Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STK17A | Q9UEE5 | 3/20 | 0.42 |
| ▸ | STK17B | O94768 | 2/20 | 0.42 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 2/20 | 0.38 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.38 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.38 |
| ▸ | FLT3 | P36888 | 3/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | KDR | P35968 | 1/20 | 0.36 |
| ▸ | RET | P07949 | 1/20 | 0.36 |
| ▸ | KIF5B | P33176 | 1/20 | 0.36 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.36 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3451732 | 0.92 | RET (0.39) | STK17ASTK17BMAP4K4POLBADORA2A | |
| SCHEMBL3447677 | 0.91 | MAP4K4 (0.40) | STK17ASTK17BMAP4K4POLBADORA2A | |
| SCHEMBL3449219 | 0.89 | KCNH2 (0.46) | STK17ASTK17BMAP4K4POLBADORA2A | |
| SCHEMBL3449785 | 0.87 | ADORA2A (0.40) | STK17ASTK17BMAP4K4POLBADORA2A | |
| SCHEMBL3450862 | 0.87 | ROCK2 (0.36) | STK17ASTK17BMAP4K4POLBADORA2A | |
| SCHEMBL3449074 | 0.87 | FLT3 (0.44) | MAP4K4POLBADORA2AADORA1FLT3 | |
| SCHEMBL3450353 | 0.86 | RET (0.40) | MAP4K4POLBADORA2AADORA1FLT3 | |
| SCHEMBL3449748 | 0.85 | RPS6KA3 (0.40) | STK17ASTK17BMAP4K4POLBADORA2A | |
| SCHEMBL3449767 | 0.85 | ADORA2A (0.39) | STK17ASTK17BMAP4K4ADORA2AADORA1 | |
| SCHEMBL3450369 | 0.84 | RET (0.42) | MAP4K4POLBADORA2AADORA1FLT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100137313-A1 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | ASTRAZENECA AB | 2010-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137313-A1 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | SDHA, SDHB, UROD | STK17A 1984/4885STK17B 2457/4885MAP4K4 3478/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.